Novo Nordisk
Novo Nordisk
NOV
XETR
96.52
EUR
-4.28%
About
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem.
As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 1.8M |
| Three Month Average Volume | 52.1M |
| High Low | |
| Fifty-Two Week High | 138.51324 EUR |
| Fifty-Two Week Low | 82.35451 EUR |
| Fifty-Two Week High Date | 26 Jun 2024 |
| Fifty-Two Week Low Date | 04 Oct 2023 |
| Price and Volume | |
| Current Price | 124.55734 EUR |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | 1.92% |
| Thirteen Week Relative Price Change | 0.12% |
| Twenty-Six Week Relative Price Change | 1.07% |
| Fifty-Two Week Relative Price Change | 14.88% |
| Year-to-Date Relative Price Change | 11.37% |
| Price Change | |
| One Day Price Change | -0.96% |
| Thirteen Week Price Change | 0.56% |
| Twenty-Six Week Price Change | 5.92% |
| Five Day Price Change | 2.87% |
| Fifty-Two Week Price Change | 42.81% |
| Year-to-Date Price Change | 33.09% |
| Month-to-Date Price Change | -0.96% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 3.20432 EUR |
| Book Value Per Share (Most Recent Quarter) | 3.41528 EUR |
| Tangible Book Value Per Share (Last Fiscal Year) | 1.38789 EUR |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.73071 EUR |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | 3.79277 EUR |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 6.92744 EUR |
| Revenue Per Share (Trailing Twelve Months) | 7.72876 EUR |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | 1.26019 EUR |
| Dividend Per Share (Trailing Twelve Months) | 1.32722 EUR |
| Dividend Per Share (5 Year) | 0.79164 EUR |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | 2.49594 EUR |
| Excluding Extraordinary Items (Trailing Twelve Months) | 2.69288 EUR |
| Normalized (Last Fiscal Year) | 2.54658 EUR |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | 2.50262 EUR |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | 2.70545 EUR |
| Including Extraordinary Items (Last Fiscal Year) | 2.49594 EUR |
| Including Extraordinary Items (Trailing Twelve Months) | 2.69288 EUR |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.88326 EUR |
| Cash Per Share (Most Recent Quarter) | 1.90168 EUR |
| Cash Flow Per Share (Last Fiscal Year) | 2.71334 EUR |
| Cash Flow Per Share (Trailing Twelve Months) | 2.97614 EUR |
| Free Cash Flow Per Share (Trailing Twelve Months) | 0.72014 EUR |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | 16 |
| Cash Flow Revenue (Trailing Twelve Months) | 9 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | 43.77% |
| Pretax Margin (Last Fiscal Year) | 45.07% |
| Pretax Margin (5 Year) | 41.87% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 84.60% |
| Gross Margin (Trailing Twelve Months) | 84.53% |
| Gross Margin (5 Year) | 83.93% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | 44.16% |
| Operating Margin (Trailing Twelve Months) | 43.20% |
| Operating Margin (5 Year) | 42.88% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | 36.03% |
| Net Profit Margin (Trailing Twelve Months) | 34.84% |
| Net Profit Margin (5 Year) | 33.55% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 14.41% |
| Tangible Book Value (5 Year) | -0.23% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | 23.03% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 25.34% |
| Revenue Growth (3 Year) | 15.74% |
| Revenue Change (Trailing Twelve Months) | 28.15% |
| Revenue Per Share Growth | 17.51% |
| Revenue Growth (5 Year) | 22.31% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 25.67% |
| Total Debt (5 Year) | 120.77% |
| Dividends | |
| Dividend Growth (3 Year) | 27.36% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 4.06% |
| EPS Change (Trailing Twelve Months) | 35.45% |
| EPS Growth (3 Year) | 18.50% |
| EPS Growth (5 Year) | 27.40% |
| EBITDA | |
| EBITDA (5 Year) | 17.01% |
| EBITDA (5 Year Interim) | 18.20% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | 0.85% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 68 |
| Price to Tangible Book (Most Recent Quarter) | 55 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | 82 |
| Price to Free Cash Per Share (Trailing Twelve Months) | 131 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -5,594,000,000 |
| Net Debt (Last Fiscal Year) | -2,367,000,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 14 |
| Price to Sales (Trailing Twelve Months) | 12 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | 46 |
| PE Normalized (Last Fiscal Year) | 49 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | 50 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 50 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 22 |
| PE Including Extraordinary Items (Trailing Twelve Months) | 46 |
| Dividends | |
| Dividend Yield (5 Year) | 1.52% |
| Dividend Yield | 1.07% |
| Current Dividend Yield | 1.07% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 39 |
| Price to Book (Most Recent Quarter) | 36 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 19 |
| Long Term Debt to Equity (Most Recent Quarter) | 46 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | 50.17% |
| Payout Ratio (Trailing Twelve Months) | 46.71% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 1 |
| Quick Ratio (Most Recent Quarter) | 1 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | 155 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | 390 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | 38.2B |
| Free Cash Flow (Trailing Twelve Months) | 24.0B |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 25 |
| Total Debt to Equity (Most Recent Quarter) | 51 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | 30.12% |
| Return on Assets (Trailing Twelve Months) | 27.66% |
| Return on Assets (5 Year) | 29.17% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | 88.07% |
| Return on Equity (Trailing Twelve Months) | 88.57% |
| Return on Equity (5 Year) | 75.65% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | 63.12% |
| Return on Investment (Trailing Twelve Months) | 58.83% |
| Return on Investment (5 Year) | 58.62% |